Markets

Reduce Sun Pharma, target Rs 482: Elara Capital

  • Digg
  • Google Bookmarks
  • StumbleUpon
  • Reddit
  • Newsvine
  • Live Bookmarks
  • Technorati
  • Yahoo Bookmarks
  • Blogmarks
  • Del.icio.us
  • ApnaCircle
  • Google Plus
  • Pinterest

ETMarkets.com|

Updated: Jun 15, 2018, 10.20 AM IST

Elara Capital has a reduce call on Sun Pharmaceutical Industries Ltd. with a target price of Rs 482.

Company Summary

ADD TO PORTFOLIO

ADD TO WATCHLIST

SHARE YOUR OULOOK

ChartsValuation & Peer ComparisonCommunity Buzz

Elara Capital has a reduce call on Sun Pharmaceutical Industries Ltd. with a target price of Rs 482 . The current market price of Sun Pharmaceutical Industries Ltd. is Rs 569.25 Time period given by the brokerage is a year when Sun Pharmaceutical Industries Ltd. price can reach defined target. .

Sun Pharmaceutical Industries Ltd., incorporated in 1993, is a largecap company with a market cap of Rs 134278.20 crore.

Investment rationale by Elara Capital

Halol clearance provides comfort on Suns achievement of guidance of early double-digit revenue growth in FY19. Focus would shift back to earnings quality and ramp-up in the specialty business. The stock has seen a 10% run-up over past three trading days post FDA status of VAI on the Halol facility. At the CMP, the stock is trading at rich valuations of 25x FY20E P/E and factors in the Halol clearance, in our view. We retain Reduce with a TP of INR 482 based on 22x FY20E P/E.

Read this article in :HindiRead more on

Also Read

Reduce CESC, target Rs 970: Elara Capital

Accumulate Cyient, target Rs 900: Elara Capital

Accumulate Tata Motors, target Rs 362: Elara Capital

Accumulate ABB India, target Rs 1390: Elara Capital

3 IT stocks Ravi Menon of Elara Capital is bullish on

Commenting feature is disabled in your country/region.

Disclaimer: This recommendation is analyst's own and does not represent those of economictimes.com & ETMarkets.com. Please consult your financial advisor before taking any position in the stock/s mentioned.

From Around The Web

More from The Economic Times

Original Article

[contf] [contfnew]

ET Markets
[contfnewc] [contfnewc]

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *